ReviewReviews in endocrine & metabolic disorders2024
Special features on insulin resistance, metabolic syndrome and vascular complications in hypopituitary patients.
Review in Reviews in endocrine & metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A Cross-Sectional Analysis of Musculoskeletal and Functional Outcomes in Patients with Pituitary Disorders: Frailty and Sarcopenia.Journal of clinical medicine · 2026Article
- Multi-omics profiling and cellular validation reveal distinct lipid networks of krill oil and its predicted mechanisms against insulin resistance.Frontiers in nutrition · 2026Article
- Article
- Sex-Specific Cardiovascular Risks and Mortality in Patients with Panhypopituitarism: A Nationwide Cohort Study.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- GHRH in diabetes and metabolism.Reviews in endocrine & metabolic disorders · 2025Review
- Long-Term IGF-1 Maintenance in the Upper-Normal Range Has Beneficial Effect on Low-Grade Inflammation Marker in Adults with Growth Hormone Deficiency.International journal of molecular sciences · 2025Article
- Biological poisons targeting the pituitary gland: insights across the five kingdoms.Frontiers in endocrinology · 2025Review
- The interplay of factors in metabolic syndrome: understanding its roots and complexity.Molecular medicine (Cambridge, Mass.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary hormone deficiency, hypopituitarism, is a dysfunction resulting from numerous etiologies, which can be complete or partial, and is therefore heterogeneous. This heterogeneity makes it difficult to interpret the results of scientific studies with these patients.Adequate treatment of etiologies and up-to-date hormone replacement have improved morbidity and mortality rates in patients with hypopituitarism. As GH replacement is not performed in a reasonable proportion of patients, especially in some countries, it is essential to understand the known consequences of GH replacement in each subgroup of patients with this heterogeneous dysfunction.In this review on hypopituitarism, we will address some particularities regarding insulin resistance, which is no longer common in these patients with hormone replacement therapy based on current guidelines, metabolic syndrome and its relationship with changes in BMI and body composition, and to vascular complications that need to be prevented taking into account the individual characteristics of each case to reduce mortality rates in these patients.
Indexed as
Identifiers
38270844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.